31.5 C
Vientiane
Saturday, October 4, 2025
spot_img
Home Blog Page 165

Nuix Wins Multiyear Contract with German Tax Authority to Strengthen Investigative and Regulatory Capabilities

SYDNEY, Sept. 18, 2025 /PRNewswire/ — Nuix (‘the Company’, ASX: NXL) today announces it has won a multiyear contract to supply forensic analysis software to the tax authority of German state Rhineland-Palatinate (Landesamt für Steuern Rheinland-Pfalz).

Nuix Neo automates workflows, ingesting data from over 1,000 file types at scale. Using responsible AI, advanced automation, and deep link-analysis, the software enables investigators to uncover the truth in vast, complex datasets and collaborate in real time. Nuix delivers consistent, auditable, and defensible results, bringing critical evidence to the surface.

Globally, Nuix supports tax authorities, integrity agencies, and other regulators in centralising and analysing large datasets to help investigators detect financial irregularities, strengthen tax compliance, and enhance the efficiency of investigative processes.

Jonathan Rubinsztein, CEO of Nuix, said: “This partnership underscores why nearly 100 regulators worldwide trust Nuix for their most complex investigations. As the go-to technology for regulators worldwide, we’re proud to support the State Tax Authority for Rhineland-Palatinate in driving regulatory excellence and uncovering truth.

“Our partnership with the State Tax Authority for Rhineland-Palatinate reflects a shared vision for innovation and integrity in regulatory work. We’re proud to help them achieve their goals.”

Stefan Dörn, Project Manager in the Tax Administration of Rhineland- at Landesamt für Steuern Rheinland-Pfalz, said: “Following a Europe-wide tender process, we chose Nuix which offered the best solution for our organization. Its technology can help streamline and accelerate our audits and investigations to more efficiency.”

Contact:
Alice Ridgway 
alice.ridgway@nuix.com

NYSE Content Advisory: Annual International Day Slate Announced

NEW YORK, Sept. 18, 2025 /PRNewswire/ — The New York Stock Exchange will hold the 2nd annual NYSE International Day, on October 23, 2025, celebrating global business excellence and fostering cross-border innovation and investment. The event is designed to bring together C-suite executives of international innovators, PE/VC investors, and the NYSE listed community for a half-day of insightful discussions, networking, and product showcases, followed by a networking reception on the Trading Floor.

NYSE Content Advisory: Annual International Day Slate Announced
NYSE Content Advisory: Annual International Day Slate Announced

International companies from regions including Canada, UK/Europe, MEA, APAC and Latin America will showcase products and innovations during networking breaks. Scheduled sessions will include discussions on the future of fintech, scaling businesses beyond borders globally, future mobility innovations, exit strategies balancing M&A and IPOs, and bridging private and public markets for late-stage companies.

Announced speakers include:

  • Jim Cramer, CNBC host, who will deliver the Opening Keynote interview alongside NYSE President Lynn Martin
  • Scarlett Sieber, Chief Strategy & Growth Officer, Money20/20
  • Frederik Thomasen, Head of Equity Capital Markets, Norges Bank Investment Management (NBIM)
  • Anu Aiyengar, Managing Director, Global Head of Advisory and Mergers & Acquisitions, J.P. Morgan
  • Masaki (Mory) Morimoto, President, The House of Suntory
  • Wen Han, Founder, Chairman & CEO, Windrose Technology

Click here to REGISTER and learn more about NYSE International Day

 

Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025

–Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo.

–Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile. Treatment emergent adverse events (TEAEs) in the denifanstat (ASC40) group were comparable to placebo: 58.6% versus 56.3%. The majority of TEAEs were mild (Grade 1) or moderate (Grade 2).

–Pre-New Drug Application (NDA) consultation of denifanstat (ASC40) with the China National Medical Products Administration (NMPA) is ongoing and feedback received from NMPA so far is encouraging. Ascletis plans to submit an NDA for denifanstat (ASC40) for the treatment of moderate to severe acne vulgaris to NMPA after completing its pre-NDA consultation.

HONG KONG, Sept. 18, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today that the oral presentation of the Phase III study results of denifanstat (ASC40) for the treatment of moderate to severe acne vulgaris (NCT06192264) was presented in the Late Breaking News sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France on September 17, 2025.

Details of the Oral Presentation

Title: First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase Ⅲ Randomised Placebo Controlled Trial

Presenter: Dr. Leihong (Flora) XIANG, M.D and Ph.D., Principal Investigator of denifanstat (ASC40) Phase III study, Department of Dermatology, Huashan Hospital, Fudan University

The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat (ASC40) once-daily oral tablet in 480 patients with moderate to severe acne vulgaris. Patients were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg denifanstat (ASC40) oral tablet once daily or matching placebo for 12 weeks. Baseline characteristics were well balanced between denifanstat (ASC40) and placebo arms.

Primary endpoints included the percent treatment success, defined as an Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12, the percent reductions from baseline to week 12 in total lesion count (TLC), and the percent reduction from baseline to week 12 in inflammatory lesion count (ILC).

After 4-week treatment, the denifanstat (ASC40) group already showed statistically significant improvements (p<0.05) over placebo in multiple efficacy endpoints, including treatment success, TLC, ILC, and non-inflammatory lesion count (NILC).

After 12-week treatment, denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints. Table 1 summarizes efficacy results from the Phase III study versus placebo (intent-to-treat, ITT analysis). 

Table 1. Efficacy results from the Phase III study versus placebo (intent-to-treat, ITT analysis)

Efficacy endpoints (1)

50 mg
denifanstat (ASC40), oral,
once daily

(n=240)

Placebo,
oral, once
daily

(n=240)

Placebo

adjusted

 

P value

 

Primary endpoints

Percent treatment

success (2)

33.17

14.58

18.59

<0.0001

Percent reduction from
baseline in TLC

57.38

35.42

21.96

<0.0001

Percent reduction from
baseline in ILC

63.45

43.21

20.24

<0.0001

Key secondary endpoint

Percent reduction from
baseline in NILC

51.85

28.94

22.91

<0.0001

Secondary endpoints

Absolute reduction from
baseline in TLC

58.25

36.17

22.08

<0.0001

Absolute reduction from
baseline in ILC

26.56

18.42

8.14

<0.0001

Notes:

(1)  All efficacy endpoints are least square means.

(2)  Treatment success is defined as an Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12.

(3) TLC: total lesion count; ILC: inflammatory lesion count; NILC: non-inflammatory lesion count.

Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile following 12 weeks of once-daily oral administration at 50 mg. The incidence rates of treatment-emergent adverse events (TEAEs) were comparable between denifanstat (ASC40) and placebo: 58.6% versus 56.3%. No incidence rates of TEAEs related to study drug in any category exceeded 10%. Only two categories of TEAEs had an incidence rate of more than 5% (6.3% dry skin in denifanstat (ASC40) -treated patients versus 2.9% in the placebo group; 5.9% xerophthalmia in denifanstat (ASC40) -treated patients versus 3.8% in the placebo group). The majority of TEAEs were mild (Grade 1) or moderate (Grade 2). All denifanstat (ASC40) -related TEAEs were mild (Grade 1) or moderate (Grade 2). There were no denifanstat (ASC40) -related Grade 3 or 4 TEAEs and no denifanstat (ASC40) -related serious AEs (SAEs). No deaths were reported. No denifanstat (ASC40) -related permanent treatment discontinuations or withdrawals were observed.

Detailed data presented at the EADV Congress 2025 can be found at Ascletis’ website (link).

“Denifanstat (ASC40) is an innovative and potentially meaningful advancement for the treatment of acne and we’re very pleased that we have presented these results to the dermatology community at this year’s EADV Congress,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “Denifanstat (ASC40) has a new mechanism of action for acne treatment and demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary and secondary endpoints in the Phase III study, as well as a favorable safety and tolerability profile.”

Pre-New Drug Application (NDA) consultation of denifanstat (ASC40) with the China National Medical Products Administration (NMPA) is ongoing and feedback received from NMPA so far is encouraging. Ascletis plans to submit an NDA for denifanstat (ASC40) for the treatment of moderate to severe acne vulgaris to NMPA after completing its pre-NDA consultation.

Ascletis licensed denifanstat (ASC40) from Sagimet Biosciences Inc. (Nasdaq: SGMT) for exclusive rights in Greater China.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform and Ultra-Long-Acting Platform (ULAP), Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

To learn more about Ascletis, please visit www.ascletis.com.

Contact:

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com

MagicRNA’s First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.

  • First-ever clinical data supporting safety and efficacy of in vivo CAR-T Therapy in refractory systemic lupus erythematosus (SLE) patients.
  • Data shows low dose of HN2301 reprogrammed up to 60% of CD8+ CAR+ T-cells in the peripheral blood of patients, resulting in complete depletion of circulating B cells and up to 20-points reduction in patient’s SLEDAI scores within three months.
  • Favourable safety profile with no neurotoxic effects or other severe adverse events, no clinically significant elevation of liver enzymes was observed during or after treatment in any of the 5 patients.

SHENZHEN, China, Sept. 18, 2025 /PRNewswire/ — MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world’s first clinical data of an mRNA-lipid nanoparticle (mRNA-LNP) based in vivo CAR T candidate, HN2301, in The New England Journal of Medicine. The study, titled “In vivo CD19-CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus”, represents the first-ever demonstration of in vivo CAR T generation and activity in SLE patients.

“This study is an important milestone for the entire field of cell therapy,” said Prof. Georg Schett, pioneer in the use of CD19 CAR T cell therapy in SLE and achieved a revolutionary breakthrough. “For the first time, we see functional CAR T cells generated directly in patients’ body, achieving rapid B-cell clearance and clinical improvement of autoimmune disease. These findings, together with the favorable safety profile, pave the way for a new era of immunotherapy.”

The clinical trial enrolled five patients with long-standing, treatment-refractory SLE, four of whom also had lupus nephritis. Built on MagicRNA’s EnC-LNP delivery platform technology, HN2301 was administered intravenously without prior lymphodepletion to deliver CAR-encoding mRNA to CD8+ T cells, reprogramming them into CD19-targeted CAR T cells in vivo.

“This study marks the first clinical proof-of-concept of the cell targeted-LNP based in vivo CAR T-cell in autoimmune disease, validating its therapeutic potential in patients,” said Dr. Gavin Zha, CEO of MagicRNA. “By achieving deep B-cell depletion, in vivo CAR T technology offers a new level of disease control that potentially goes beyond what has been achieved with conventional approaches such as monoclonal antibodies and T-cell engagers. At the same time, it overcomes the major limitations of ex vivo CAR T therapies, including complex manufacturing, long preparation times, high costs, and the requirement for lymphodepletion. Our platform has the potential to make transformative cell therapies broadly accessible and scalable for patients.”

At a minimal dose (2 mg per infusion), single or repeated administration of HN2301 induced CAR T-cells generation and B-cell reduction. At a bit higher dose (4 mg per infusion) up to 60% of CD8+ CAR+T-cells were reprogrammed within six hours, leading to complete depletion of circulating B cells, which persisted for 7-10 days. Consistent with B-cell depletion, anti-nucleosome and anti-dsDNA antibodies significantly decreased, and low complement levels in some patients normalized at the last visit. In addition, Disease Activity Index (SLEDAI-2000) scores significantly decreased by as much as 20 points in all 5 patients 3 months after the infusion of HN2301. The treatment was generally well tolerated, no patients experienced grade ≥3 CRS, and no neurotoxic effects or other severe adverse events were observed during or after treatment.

Based on these encouraging clinical results, MagicRNA will continue the dose-escalation studies to further evaluate HN2301’s ability to achieve immune reset and long-term drug-free remission, with the goal of accelerating clinical development and ultimately bringing this therapy to patients worldwide.

About HN2301
HN2301 is MagicRNA’s lead investigational therapy and the world’s first in vivo CAR T candidate to enter clinical testing in SLE patients. HN2301 encapsulates CD19 CAR-encoding mRNA in a proprietary T-cell-targeted lipid nanoparticle (EnC-LNP), enabling direct reprogramming of patient T cells into functional CAR T cells in vivo. In preclinical studies, including nonhuman primates and mouse models, HN2301 achieved rapid and robust CAR T reprogramming and complete depletion of B cells in blood and tissues. Early first-in-human data demonstrated feasibility, clinical efficacy, and favourable safety profile.

About MagicRNA
MagicRNA Biotechnology, founded in 2021, is a clinical-stage biotech company pioneering next-generation mRNA and lipid nanoparticle (LNP) technologies to expand the reach of RNA-based medicines. The company’s proprietary Engineered Cell-targeted LNP (EnC-LNP) platform enables precise delivery of mRNA into non-antigen presenting cells (non-APC) outside the liver, overcoming a key limitation of conventional liver-targeted LNPs. MagicRNA is establishing itself as a global leader in the field of engineered cell-targeted LNP based therapeutics. In addition to its lead program, HN2301, MagicRNA is advancing a pipeline of in vivo cell reprogramming therapeutics and cell-targeted LNP based medicines across immune-related diseases.

About SLE
Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease affecting an estimated 3.4 million people globally, with a prevalence of approximately 44 per 100,000 individuals. The disease disproportionately affects women of childbearing age and is characterized by immune-mediated inflammation and tissue damage across multiple organs, with lupus nephritis being one of the most severe and life-threatening manifestations. Traditional standard treatments for SLE, including corticosteroids, immunosuppressants, and biologics, can help control symptoms, but many patients continue to experience recurrent relapses driving progressive multiple-tissue damage and life-threatening complications. B cells play a pivotal role in the pathogenesis of SLE by producing autoantibodies, and the “B cell reset”-induced drug-free remission of SLE has been extensively validated by clinical reports.

MagicRNA Contacts
info@magicrna.com
www.magicrna.com

Media:
Shirley.lu@bfcgroup.biz
Wendy.li@bfcgroup.biz 

UN Secretary-General appoints CEO of Naver to the UN Global Compact Board

NEW YORK, Sept. 18, 2025 /PRNewswire/ — UN Secretary-General António Guterres, who serves as Board Chair of the UN Global Compact, today welcomed Choi Soo-yeon, CEO of Naver, to the UN Global Compact Advisory Board. The UN Global Compact is the world’s largest corporate sustainability initiative.

Choi Soo-yeon became the CEO of Naver, South Korea’s biggest internet company, in 2022. She is its second female CEO and its youngest non-founder CEO. A corporate/M&A lawyer by training at Yulchon and an LL.M. graduate of Harvard Law School (2018), she rejoined NAVER in 2019 to lead global business initiatives before taking the helm. As CEO, she is driving NAVER’s AI-first global expansion—rolling out “on-service AI” across core products and launching NAVER Ventures in the United States to back high-potential startups and deepen international partnerships. Her governance, responsible-tech and cross-border operating experience aligns closely with the mission of the UN Global Compact; Naver has been an active participant of the UN Global Compact since 2014.

Choi Soo-yeon brings deep expertise on how digital companies can create value and scale globally while upholding principles on responsible and sustainable business. We look forward to her participation on our Board as we mobilize business to deliver the Sustainable Development Goals,” said Sanda Ojiambo, CEO and Executive Director of the UN Global Compact. 

Lee Dong-Kurn, President of the UN Global Compact Network Korea stated “We are delighted that CEO Choi Soo-yeon has been appointed as a UN Global Compact board member, the first Korean in 17 years. We look forward to NAVER continuing to lead the establishment of a sustainable management ecosystem on the global stage and to playing an active role as a global leader through ongoing collaboration with the UN Global Compact.”

As a special initiative of the UN Secretary-General, the UN Global Compact is a call to companies everywhere to align their operations and strategies with Ten Principles in the areas of human rights, labour, environment and anti-corruption. The UN Global Compact challenges businesses to take concrete actions to accelerate progress on the Sustainable Development Goals (SDGs).

The UN Global Compact Board plays an important role in shaping the strategy and policy of the initiative, which acts as the UN flagship for responsible business action. Designed as a multi-stakeholder body, the Board provides ongoing strategic and policy advice for the initiative. Board members are considered champions who are willing and able to advance the mission of the UN Global Compact. They act in a personal, honorary and unpaid capacity.

For the current list of board members please refer to: www.unglobalcompact.org/about/governance/board/members

Notes to Editors

About the UN Global Compact
The ambition of the UN Global Compact is to accelerate and scale the global collective impact of business by upholding the Ten Principles and delivering the SDGs through accountable companies and ecosystems that enable change. With more than 20,000 participating companies, 5 Regional Hubs, 64 Country Networks covering 85 countries and 9 Country Managers establishing Networks in 16 other countries, the UN Global Compact is the world’s largest corporate sustainability initiative — one Global Compact uniting business for a better world. For more information, follow @globalcompact on social media and visit our website at unglobalcompact.org.

The fifth Guangdong-Hong Kong-Macao Greater Bay Area Culture and Arts Festival opens

GUANGZHOU, China, Sept. 18, 2025 /PRNewswire/ — The fifth Guangdong-Hong Kong-Macao Greater Bay Area Culture and Arts Festival kicked off at the Guangzhou Opera House on the evening of September 16. The festival is jointly sponsored by the Ministry of Culture and Tourism of the People’s Republic of China, the People’s Government of Guangdong Province, the Government of the Hong Kong Special Administrative Region (SAR), and the Government of the Macao SAR.

The fifth Guangdong-Hong Kong-Macao Greater Bay Area Culture and Arts Festival kicked off at the Guangzhou Opera House on the evening of September 16.
The fifth Guangdong-Hong Kong-Macao Greater Bay Area Culture and Arts Festival kicked off at the Guangzhou Opera House on the evening of September 16.

The month-long culture and arts feast features five categories of events across 11 cities: the “Arts in the Bay” performance series; “Resonance in Arts” art lectures; “Shared Aesthetics” art exhibitions; “Art in Daily Life” activities for the benefit of the public; and the “Radiance of Arts” performing arts fair. Over 100 performances, 19 exhibitions, and more than 150 community events will be held.

The festival began with the “Symphony of the Greater Bay Area” concert, where seven compositions highlighting the “GBA gene”—Guangdong’s most outstanding original symphonic works from recent years—were performed.

Multiple world-renowned classic works will be staged in the GBA, and several acclaimed international troupes have chosen the festival as their first stop in China, allowing local audiences to savor the charm of world-class art without traveling far.

Among the performances already staged was “La Traviata,” a classic opera performed by an approximately 150-member troupe from the Greek National Opera for their debut in China. Another performance was Matthew Bourne’s “Swan Lake,” renowned for its groundbreaking all-male ensemble that reimagines the classic story and is regarded as a milestone in modern ballet. Additionally, “Eugene Onegin” and “Uncle Vanya,” both classic plays produced by the century-old Vakhtangov Theatre of Russia, were praised for their embodiment of the depth and subtlety of Russian literary giants. Five internationally acclaimed musical theatre stars, including Brad Little, shared the stage for the first time at the GBA, performing 26 pieces of classic musicals.

Following that, the hit French musical “Molière” will take the stage at the Guangzhou Opera House in October, depicting the legendary life of the French theatre master Molière through its revolutionary stage aesthetics.

“Confucius,” a dance drama by the China National Opera & Dance Drama Theater, has been staged. Following that, the National Theatre of China will present the modern drama “The Yellow Storm,” while the Shanghai Yue Opera House will showcase its classic interpretation of the literary masterpiece A Dream of Red Mansions with its Yue Opera adaptation of the same name. The Guangdong Yue Opera Theatre’s production “Samsui Women” tells an inspiring story of female resilience, and the Southern Song and Dance Troupe’s “I Like You” bridges tradition and modernity by integrating Yingge Dance with musical theatre.

To further vitalize the performing arts market in the GBA and support the high-quality development of Guangdong’s performing arts market, this year’s festival encompasses the component themed “Radiance of Arts”—the 16th China (Guangzhou) International Performing Arts Fair. Scheduled from September 25 to 28, the event will bring together nearly 300 performing arts institutions from 20 countries and regions, showcasing nearly 1,000 productions.

HAMMOCK COVE ANTIGUA ELEVATES LUXURY WITH NEW SIGNATURE VILLAS AND CURATED GUEST EXPERIENCES

The 5-star resort introduces oversized plunge pools, exclusive social rituals, and immersive cultural programming for the holiday season

DEERFIELD BEACH, Fla., Sept. 18, 2025 /PRNewswire/ — Hammock Cove Antigua, part of the Elite Island Resorts collection, is redefining Caribbean luxury with the debut of its Signature Villas alongside a season of elevated cultural and social programming. Designed for discerning travelers seeking privacy, personalization, and immersive experiences, the new villas and guest offerings underscore the resort’s reputation as one of Antigua’s most refined escapes. To celebrate, guests who book by October 31, 2025, for travel through December 20, 2025, can enjoy a seventh night free plus $1,000 in instant savings, making it the perfect time to experience Hammock Cove’s unparalleled accommodations and curated experiences.

Chairman’s Lounge
Chairman’s Lounge

The Signature Villas, Hammock Cove’s newest and most luxurious accommodation category, set a new benchmark in Caribbean villa living. Featuring expansive decks with oversized plunge pools three times the size of other suites, private indoor wet bars, and separate bedroom and desk areas, the villas provide the perfect blend of seclusion and style. Guests enjoy panoramic views of Antigua’s tranquil beaches and bays, paired with thoughtful amenities including Serta Perfect Sleeper king mattresses, Egyptian cotton linens, daily turndown service, and a curated selection of books for leisurely indulgence.

“The launch of our Signature Villas is about raising the standard of luxury in Antigua,” said Adrian Pickard, General Manager of Hammock Cove. “We’ve designed these villas to give guests the privacy of a personal retreat while maintaining the full-service experience and cultural connection that define Hammock Cove.”

In addition to the new villas, Hammock Cove is rolling out a slate of distinctive seasonal programs running October 1, 2025, through April 30, 2026:

  • The Chairman’s Scotch & Cognac Club – A refined weekly gathering in the Chairman’s Lounge, limited to just 12 guests. The experience features pours of Louis XIII Cognac and Johnnie Walker Blue Label Scotch, a premium Churchill-style cigar, gourmet canapes by Michelin-starred Chef Marco, and white-glove service, creating an Instagram-worthy evening of elegance.
  • Sir Rob’s Cigar Social – A lively, social event at the resort’s Nobody Knows Bar. Guests enjoy hand-selected cigars, a flight of island rums, fun bar snacks, lighthearted games, and prizes, all designed to bring people together in a relaxed Caribbean setting.
  • Rotating Art Tunnel Exhibit & Artist Cocktail Series – A monthly celebration of Antigua’s vibrant creative community. In partnership with Quay Studio, Hammock Cove will showcase local artists through rotating exhibits in the resort’s Art Tunnel, paired with weekly cocktail receptions where guests can meet the artists, purchase works, and engage in cultural storytelling.

“Hammock Cove has always been about offering experiences that feel both luxurious and authentically Antiguan,” said Kari Tarnowski, Chief Commercial Officer of Elite Island Resorts. “From our new villas to our curated social and cultural events, we’re creating moments that inspire guests to connect with each other, the destination, and the finer things in life.”

Together, the Signature Villas and new guest programming reinforce Hammock Cove’s position as Antigua’s premier boutique luxury resort, seamlessly blending quiet luxury, cultural immersion, and modern indulgence.

For more information or to book a stay at Hammock Cove Antigua, visit https://www.hammockcoveantigua.com.

See photos here.

About Hammock Cove Antigua
Hammock Cove Antigua is a five-star, adults-only, all-inclusive resort on Antigua’s northeast coast, overlooking Devil’s Bridge National Park and the Caribbean Sea. A multi-year winner of TripAdvisor’s Travelers’ Choice Award, the resort features private villas with indoor-outdoor living spaces, plunge pools, and contemporary Caribbean decor, along with two signature restaurants offering Caribbean and Continental cuisine, sommelier-curated wine selections, and signature cocktails. Guests can enjoy wellness and spa treatments, non-motorized water sports, and personalized service from dedicated guest ambassadors, all designed to provide an exclusive and serene island retreat.

About Elite Island Resorts
Founded under the vision of the late Chairman Robert Barrett, whose leadership helped shape Antigua’s tourism industry, Elite Island Resorts is a collection of all-inclusive beachfront properties across the Caribbean and Panama. The portfolio includes Galley Bay Resort & Spa, Hammock Cove Antigua, Pineapple Beach Club Antigua, St. James’s Club & Villas, The Verandah Antigua, The Club Barbados, and Los Establos Boutique Resort Panama. Known for exceptional service, world-class amenities, and a high rate of returning guests, Elite Island Resorts creates memorable island escapes that blend local culture with immersive experiences. Barrett’s legacy of hospitality and community support continues through the brand’s partnerships and its commitment to delivering unforgettable Caribbean holidays.

Signature Villa
Signature Villa

 

Hammock Cove Antigua
Hammock Cove Antigua

 

 

Media Contact:
Malaika Hollis, Alliance Connection
malaika@allianceconnection.com

Minelab Premieres the VANQUISH 60 Series: Simple Yet Powerful

LONDON, Sept. 18, 2025 /PRNewswire/ — Minelab officially unveiled the new VANQUISH 60 Series on 11 September 2025 at a press event held at the remarkable National Gallery Museum in London. The exclusive launch welcomed media representatives, Minelab dealers, and invited guests to witness the first presentation of the new detectors.

 

Vanquish 60 Series – Lifestyle Video

The event featured a special speech by Helen Skelton, who shared her personal experiences in the field of adventure and discovery, highlighting the excitement and accessibility of metal detecting. Minelab President Ben Harvey addressed the audience with the company’s vision and innovation journey, while Minelab General Manager Engineering Mark Lawrie provided a live demonstration of the VANQUISH 60 Series, showcasing its advanced features and performance.

Following the premiere, Minelab brought the VANQUISH 60 Series to the wider detecting community at Detectival 2025 on 13 September. At the Minelab booth, visitors tested the full VANQUISH range, participated in Minelab University sessions with engineers and Detexperts, and connected directly with the brand.

Accessible Technology for All

Designed for those starting their journey in metal detecting while seeking professional performance, the VANQUISH 60 Series introduces versatile, lightweight models at a starting retail price of USD $249.00. This new generation delivers premium Minelab technology crafted to redefine expectations in entry-level detectors.

The first-generation VANQUISH Series has already been recognised for transforming what newcomers can expect from a detector. With technology traditionally reserved for higher-end models, VANQUISH opened a new category in the hobby, offering advanced features at an approachable level.

“When we launched the VANQUISH 40 Series six years ago, it was a game changer for entry-level detecting, becoming one of our most successful global product lines,” said Jeff Augustine, Minelab’s Global Vice President of Marketing. “With the new VANQUISH 60 Series, a new era begins. We’ve taken everything that made VANQUISH a success and elevated it further. Our expectations are not just to match that success, but to double it, bringing more people into the detecting community than ever before.”

Key Features of the VANQUISH 60 Series 

  • Fully Waterproof: Every model is IP68-rated, waterproof up to 5 m (16 ft), suitable for rivers, shorelines and lakes 
  • Proven Multi-IQ® Technology: Minelab’s simultaneous multi-frequency technology enables users to detect all metals, in all soils, at the same time, for more accurate target identification and fewer missed finds  
  • All-Day Power: Up to 10 hours of runtime ensures uninterrupted detecting sessions 
  • Lightweight Design: At just 1.26 kg (2.8 lbs), the VANQUISH 60 Series is easy to carry and swing for extended hunts 
  • Advanced Target Feedback: Select models feature smart discrimination with enhanced discrimination segments, iron bias control, and low-latency Bluetooth® LE Audio 

What’s Included 

Every VANQUISH detector comes with:  

  • Removable armrest with strap  
  • USB-C magnetic charging cable 
  • Getting Started Guide  

Model-specific accessories:  

  • VANQUISH 360: V10X coil 
  • VANQUISH 460: V10X coil and wired headphones  
  • VANQUISH 560: V12X and wired headphones  
  • VANQUISH 560 Pro-Pack: V12X and V8X coils and ML60 low-latency Bluetooth® LE audio wireless earbuds

Availability

The VANQUISH 60 Series will be available soon through Minelab’s authorized dealers and distributors worldwide. Customers are encouraged to stay connected via Minelab’s website and social channels for official release dates and regional availability updates.

ABOUT MINELAB

Minelab is an innovative, multi-award-winning business that has scaled world markets to achieve global leadership in advanced electronic detection technologies since 1985. From gold prospecting and treasure hunting to humanitarian demining and countermine operations, Minelab products are trusted worldwide for their innovation, reliability, and performance. Headquartered in Mawson Lakes, South Australia, with regional offices in Ireland, India, UAE, Mexico, Brazil and the USA, Minelab develops and manufactures world-leading handheld detection systems for adventure, discovery, and safety.

Vanquish 60 Series - Hero Landscape
Vanquish 60 Series – Hero Landscape

 

Vanquish 60 Series - Lifestyle Beach
Vanquish 60 Series – Lifestyle Beach

 

Vanquish 60 Series - Lifestyle Beach 2
Vanquish 60 Series – Lifestyle Beach 2

 

Vanquish 60 Series - Hero
Vanquish 60 Series – Hero